Elsevier Inc.

SHERPA: Unknown

People

  1. Chung
    Chung
  2. Giralt
    Giralt
  3. Landau
    Landau
  4. Shah
    Shah
  5. Hassoun
    Hassoun
  6. Lesokhin
    Lesokhin
  7. Scordo
    Scordo
  8. Mailankody
    Mailankody
  9. Korde
    Korde
  10. Devlin
    Devlin

Groups

  1. Bone Marrow Transplant (71)
  2. Center for Hematologic Malignancies (71)
  3. Department of Medicine (71)
  4. Hematologic Malignancies, Division of (71)
  5. Survivorship Research (67)
  6. Myeloma (51)
  7. Hematologic Malignancies Research (49)
  8. CTCR Scholars (46)
  9. Epidemiology and Biostatistics (39)
  10. Biostatistics Service (38)
Search Within
  1. "Center for Hematologic Malignancies"
  2. "David Chung"
Formats
  1. Meeting Abstract (56)
  2. Journal Article (13)
  3. Research Letter (1)
  4. Review (1)
Groups
  1. Bone Marrow Transplant (71)
  2. Center for Hematologic Malignancies (71)
  3. Department of Medicine (71)
  4. Hematologic Malignancies, Division of (71)
  5. Survivorship Research (67)
  6. Myeloma (51)

More Groups

People
  1. David Chung (71)
  2. Sergio Giralt (64)
  3. Heather Landau (62)
  4. Gunjan Shah (52)
  5. Alexander Lesokhin (44)
  6. Hani Hassoun (44)

More People

Years
  1. 2024 (1)
  2. 2023 (15)
  3. 2022 (12)
  4. 2021 (3)
  5. 2020 (10)
  6. 2019 (9)

More Years

Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (33)
  2. Biology of Blood and Marrow Transplantation (28)
  3. Transplantation and Cellular Therapy (7)
  4. Best Practice and Research: Clinical Haematology (1)
  5. Clinical Biochemistry (1)
  6. eClinicalMedicine (1)

Results (71)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes and management of the SARS-CoV2 omicron variant in recipients of hematopoietic cell transplantation and chimeric antigen receptor T cell therapy
    Journal Article

    Infante, M. S.; Nemirovsky, D.; Devlin, S.; DeWolf, S.; Tamari, R.; Dahi, P. B.; Lee, Y. J.; Chung, D. J.; Politikos, I.; Barker, J.; more...
    Transplantation and Cellular Therapy (2024)

    Fulltext@MSK | Save
  • A whole foods plant-based weight loss intervention improves metabolic and immune biomarkers in MGUS/SMM patients as well as progression trajectory in a subset: The NUTRIVENTION trial
    Meeting Abstract

    Shah, U.; Derkach, A.; Castro, F.; Anuraj, A.; Blaslov, J.; Hosszu, K.; Pollak, M.; Mailankody, S.; Korde, N.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Successful incorporation of ePRO using PROMIS-29 into standard of care after hematopoietic stem cell transplant and chimeric antigen receptor T cell therapy for plasma cell dyscrasias
    Meeting Abstract

    Shah, G.; Lobaugh, S.; Devlin, S.; Atkinson, T.; Korde, N.; Chung, D.; Dahi, P.; Landau, H.; Lahoud, O.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Mailankody, S.; Lahoud, O.; Landau, H.; Chung, D.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C. R.; Maclachlan, K.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Patel, D.; Shekarkhand, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Ipilimumab after CD34-selected allogeneic stem cell transplantation (Allo HCT) for patients with relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Ghosh, A.; Nagel, K.; Hosszu, K.; Datta, A.; Thompson, C.; Levia, K.; Kamrowski, A.; McAvoy, D.; Chung, D.; Landau, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evolving M-spike and risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Nemirovsky, D.; Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Adding Plinabulin to pegfilgrastim to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant for multiple myeloma
    Meeting Abstract

    Shah, G.; Hanley, D.; Datta, A.; Kamrowski, A.; Chung, D.; Gupta, G.; Hassoun, H.; Hoover, E.; Hultcrantz, M.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evaluating dynamic changes in the serum free light chain ratio and its effect on risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Nemirovsky, D.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Nath, K.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save